| __timestamp | BeiGene, Ltd. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 79383000 |
| Thursday, January 1, 2015 | 7311000 | 108402000 |
| Friday, January 1, 2016 | 20097000 | 46928000 |
| Sunday, January 1, 2017 | 62602000 | 74959000 |
| Monday, January 1, 2018 | 195385000 | 79716000 |
| Tuesday, January 1, 2019 | 388249000 | 74669000 |
| Wednesday, January 1, 2020 | 600176000 | 59040000 |
| Friday, January 1, 2021 | 990123000 | 77417000 |
| Saturday, January 1, 2022 | 1277852000 | 91473000 |
| Sunday, January 1, 2023 | 1504501000 | 94314000 |
Data in motion
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of BeiGene, Ltd. and MannKind Corporation from 2014 to 2023. Over this period, BeiGene's SG&A expenses skyrocketed by over 21,000%, reflecting its aggressive expansion and investment in global operations. In contrast, MannKind's expenses remained relatively stable, with a modest increase of about 19%. This stark difference highlights BeiGene's rapid growth strategy compared to MannKind's more conservative approach. By 2023, BeiGene's SG&A expenses were approximately 16 times higher than MannKind's, underscoring its significant market presence. This financial trajectory offers a glimpse into the strategic priorities of these two biotech giants, with BeiGene focusing on scaling and MannKind maintaining steady operations.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Summit Therapeutics Inc.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Pharming Group N.V.
Comparing SG&A Expenses: BeiGene, Ltd. vs ADMA Biologics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Travere Therapeutics, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs MannKind Corporation Trends and Insights
Who Optimizes SG&A Costs Better? PTC Therapeutics, Inc. or MannKind Corporation
Bausch Health Companies Inc. vs MannKind Corporation: SG&A Expense Trends
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs MannKind Corporation Trends and Insights
Supernus Pharmaceuticals, Inc. and MannKind Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for Iovance Biotherapeutics, Inc. and MannKind Corporation